Researchers at the Jacksonville, Fla., campus of Rochester, Minn.-based Mayo Clinic have been awarded a $13.3 million, five-year federal grant to test a vaccine that aims to prevent the recurrence of triple-negative breast cancer.
The grant is funded through the U.S. Department of Defense's Breast Cancer Research Program and Breakthrough Award. It will fund the second phase of Mayo's clinical trial, which will enroll 280 patients across the country and test the ability of a folate receptor alpha vaccine to prevent recurrence of triple-negative breast cancer following initial treatment.
The folate receptor alpha vaccine was designed by the grant's principal investigator, Keith Knutson, PhD, and was initially tested by researchers at Mayo Clinic's Rochester campus for safety and efficacy.
The newly funded trial is scheduled to begin in early 2016.
More articles on breast cancer:
Up to 17M women could lose mammogram coverage
IBM Watson partners with 14 cancer centers to identify personalized treatments
$4B: The annual national cost for false-positive mammograms and breast cancer overdiagnoses